SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, TCR

February 09, 2022

Lete-cel’s Readout Anticipated For 2023; New GSK Expected to Launch by Mid-2022; GSK’s Q4 2021 Earnings Call Summary

Here is a brief preview of this blast: On Wednesday, February 9, GSK held their Q4 2021 earnings call (press release / presentation). Of note, management presented lete-cel’s (NY-ESO-1 TCR-T) upcoming clinical updates and highlighted that GSK’s business separation is anticipated by mid-2022. Below, Celltelligence provides insights on potential approval timelines for lete-cel and how it compares to Adaptimmune’s afami-cel (MAGE-A4 SPEAR-T).

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.